New Results
A cannabinoid receptor agonist shows anti-inflammatory and survival properties in human SARS-CoV-2-infected iPSC-derived cardiomyocytes
View ORCID ProfileLuiz Guilherme H. S. Aragão, Júlia T. Oliveira, Jairo R. Temerozo, Mayara A. Mendes, José Alexandre Salerno, Carolina da S. G. Pedrosa, Teresa Puig-Pijuan, Carla Veríssimo, Isis M. Ornelas, Thayana Torquato, Gabriela Vitória, Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Suelen da Silva Gomes Dias, Vinicius Cardoso Soares, Leticia R. Q. Souza, Karina Karmirian, Livia Goto-Silva, Diogo Biagi, Estela M. Cruvinel, Rafael Dariolli, Daniel R. Furtado, Patrícia T. Bozza, Helena L. Borges, Thiago Moreno L. Souza, View ORCID ProfileMarília Zaluar P. Guimarães, View ORCID ProfileStevens Rehen
doi: https://doi.org/10.1101/2021.02.20.431855
Luiz Guilherme H. S. Aragão
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
Júlia T. Oliveira
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
Jairo R. Temerozo
bNational Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
cLaboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
Mayara A. Mendes
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
José Alexandre Salerno
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
jInstitute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
Carolina da S. G. Pedrosa
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
Teresa Puig-Pijuan
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
hCarlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
Carla Veríssimo
jInstitute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
Isis M. Ornelas
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
Thayana Torquato
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
Gabriela Vitória
Carolina Q. Sacramento
dLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
eNational Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
Natalia Fintelman-Rodrigues
dLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
eNational Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
Suelen da Silva Gomes Dias
dLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
Vinicius Cardoso Soares
dLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
fProgram of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
Leticia R. Q. Souza
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
Karina Karmirian
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
jInstitute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
Livia Goto-Silva
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
Diogo Biagi
gPluricell Biotech, São Paulo, SP, Brazil
Estela M. Cruvinel
gPluricell Biotech, São Paulo, SP, Brazil
Rafael Dariolli
gPluricell Biotech, São Paulo, SP, Brazil
iDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Daniel R. Furtado
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
Patrícia T. Bozza
dLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
Helena L. Borges
jInstitute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
Thiago Moreno L. Souza
dLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
eNational Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
Marília Zaluar P. Guimarães
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
jInstitute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
Stevens Rehen
aD’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
jInstitute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
Article usage
Posted February 21, 2021.
A cannabinoid receptor agonist shows anti-inflammatory and survival properties in human SARS-CoV-2-infected iPSC-derived cardiomyocytes
Luiz Guilherme H. S. Aragão, Júlia T. Oliveira, Jairo R. Temerozo, Mayara A. Mendes, José Alexandre Salerno, Carolina da S. G. Pedrosa, Teresa Puig-Pijuan, Carla Veríssimo, Isis M. Ornelas, Thayana Torquato, Gabriela Vitória, Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Suelen da Silva Gomes Dias, Vinicius Cardoso Soares, Leticia R. Q. Souza, Karina Karmirian, Livia Goto-Silva, Diogo Biagi, Estela M. Cruvinel, Rafael Dariolli, Daniel R. Furtado, Patrícia T. Bozza, Helena L. Borges, Thiago Moreno L. Souza, Marília Zaluar P. Guimarães, Stevens Rehen
bioRxiv 2021.02.20.431855; doi: https://doi.org/10.1101/2021.02.20.431855
A cannabinoid receptor agonist shows anti-inflammatory and survival properties in human SARS-CoV-2-infected iPSC-derived cardiomyocytes
Luiz Guilherme H. S. Aragão, Júlia T. Oliveira, Jairo R. Temerozo, Mayara A. Mendes, José Alexandre Salerno, Carolina da S. G. Pedrosa, Teresa Puig-Pijuan, Carla Veríssimo, Isis M. Ornelas, Thayana Torquato, Gabriela Vitória, Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Suelen da Silva Gomes Dias, Vinicius Cardoso Soares, Leticia R. Q. Souza, Karina Karmirian, Livia Goto-Silva, Diogo Biagi, Estela M. Cruvinel, Rafael Dariolli, Daniel R. Furtado, Patrícia T. Bozza, Helena L. Borges, Thiago Moreno L. Souza, Marília Zaluar P. Guimarães, Stevens Rehen
bioRxiv 2021.02.20.431855; doi: https://doi.org/10.1101/2021.02.20.431855
Subject Area
Subject Areas
- Biochemistry (11744)
- Bioengineering (8751)
- Bioinformatics (29193)
- Biophysics (14968)
- Cancer Biology (12094)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14178)
- Epidemiology (2067)
- Evolutionary Biology (18303)
- Genetics (12244)
- Genomics (16801)
- Immunology (11866)
- Microbiology (28082)
- Molecular Biology (11592)
- Neuroscience (60959)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4957)
- Plant Biology (10427)
- Synthetic Biology (2885)
- Systems Biology (7339)
- Zoology (1651)